Navigation Links
FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting
Date:12/29/2011

rmation on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Dec. 29, 2011 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
2. Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries
3. Anthera Announces Completion of Safety Review by DSMB for VISTA-16
4. Homecare Providers and Consumer Advocates Urge Congress to Stop Ineffective Medicare Payment Review Process for Mobility Equipment
5. M&A Surges, Companion Diagnostics Accelerate, and Early Detection Offers New Prospects, Finds PwCs Biennial Review of the In Vitro Diagnostics Industry
6. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
7. Avreo Previews Version 7 RIS/PACS at RSNA
8. Futuremed and Cardinal Health Canada Inc. Report on Developments in Competition Bureau Review of the Proposed Acquisition
9. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
10. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
11. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 5, 2011 ORBIS and its global team of ... in Ulaanbaatar, Mongolia (June 19 - July 7) aboard ... hospital with wings. The mission was supported by Alcon ... a three-week ophthalmic skills exchange and surgical program through ...
...   The world-renowned International Journal ... addresses the thermal,aspects of radiofrequency exposure on human health. ... the controversies,surrounding huge growth and use of wireless communication. ... a quantitative,assessment of the effects of thermal energy on ...
Cached Medicine Technology:ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 2ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 3ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 4Is Heat From Radiofrequency Exposure Damaging Human Health? 2Is Heat From Radiofrequency Exposure Damaging Human Health? 3
(Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... Men and women of all ages are invited to enjoy this 5-day health ... ... Dr. John Spencer,Ellis invites men and women of all ages to enjoy a ... Ellis,welcomes anyone who has completed a fitness program from around the world,as well ...
... boosted pregnancy chances , , THURSDAY, Feb. 7 (HealthDay News) ... chances of becoming pregnant by up to 65 percent ... , , About 10 percent to 15 percent of ... vitro fertilization, in which a woman,s egg is fertilized ...
... ORBIS International is,saddened to announce the death ... of,directors, the Honorable Oliver Foot. He was 61 ... Oliver,s dedication to reduce human suffering caused ... a nonprofit global development,organization that transcends cultural, political ...
... with a certain gene variant drank less and ... the variant while taking the medication naltrexone, according ... Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies and ... 87 percent of patients with the variant who ...
... CHASE, Md., Feb. 7 This week the,Office ... a statement that "Mr.,Heath Ledger died as the ... oxycodone, hydrocodone, diazepam, temazepam, alprazolam and,doxylamine ...We have ... accident,resulting from the abuse of prescription medications." This ...
... Finding Health and Mental Health Top the List,of Needs, ... series of tornadoes in decades, many people across the ... Cross continues to help,provide meals, shelter and clean up ... welcome help comes from Red Cross health and mental,health ...
Cached Medicine News:Health News:QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravo's The Real Housewives of Orange County 2Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3Health News:ORBIS International Announces the Death of the Honorable Oliver Foot, President and Board Member 2Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 3
... almost all its mechanical strength throughout the ... 915 months. Blunt thread design assists in ... maximize surgeons options. Driver design distributes ... help prevent the screw from breaking or ...
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
... Screw System is part of a series of ... screws ranging from 3.5 to 8.0 mm. Matching ... the system provides convenience and flexibility for the ... mm system may be customized using two of ...
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Medicine Products: